When IHC was used to profile TMAs from various stages of prostate cancer progression, including primary, castration-resistant prostate cancer (CRPC), lymph node metastases, and decalcified full-face sections from bone metastases, more than 85% of all tumor samples throughout all disease progression stages showed more than 75% of all tumor cells as positive for cell surface STEAP2. The gene discussed is STEAP2; the disease is prostate cancer.